Dr bindu singh

Assistant Professor
bsingh@iiserb.ac.in
Phone: +91 755 269 1453
Group Homepage

Profile Details

Assistant Professor (July 2024- till date): Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India.
Post-doctoral Scientist (June 2019- May 2024): Southwest National Primate Research Centre, Texas Biomedical Research Institute, San Antonio, Texas, USA.
Research Associate (March 2018- March 2019): National Institute of Immunology, New Delhi, India.
PhD (July 2012- February 2018): National Institute of Immunology, Jawaharlal Nehru University, New Delhi, India.
MSc-Biotechnology (July 2010- June 2012): Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Exemplary short talk award at the 6th Texas Tuberculosis Research Symposium at the Texas Biomedical Research Institute in April 2023.
Second place in poster presentation at 10th annual San Antonio Post-doctoral Research Forum 2022.
Recognition award for the oral presentation at 10th annual San Antonio Post-doctoral Research Forum 2022.
Awarded “2022 Forum post-doctoral fellow grant” supported by the Texas Biomed Forum for a period of two years with the award amount of $60,000.
Third place in poster presentation at 9th annual San Antonio Post-doctoral Research Forum 2021.
Recognition award for the oral presentation at 9th annual San Antonio Post-doctoral Research Forum 2021.
‘Global Health Travel Award’ for Keystone Symposium held in Banff, Alberta, Canada in 2019.
ICMR-JRF in July 2012.
General Aptitude Test in Engineering examination (GATE) conducted in February 2012 and secured All India Rank-37 and 99.65 percentile.
National Eligibility Test (NET), conducted by Council of Scientific and Industrial research in June 2012 and secured All India Rank-22.
Tuberculosis, caused by Mycobacterium tuberculosis (M.tb), is a major health concern being the 2nd top infectious killer in the world resulting in ~1.3 million deaths in 2022. India along with several other countries in Asian, African and North American sub-continent are among the high TB burden countries. With a quarter of the world’s population infected with latent TB, no vaccine for HIV yet, the HIV-TB remains a field of significant scientific challenge that needs to be addressed by integrating the advances in disease modeling from the TB field to study HIV-M.tb interactions. And to find better treatment approaches to combat these issues.

Key Questions

As discussed above, the Mtb-HIV co-infection presents an arduous situation. Treatment of Mtb-HIV infected patients by simultaneous ATT and ART therapy is complicated by drug resistant strains, drug-drug interactions, drug toxicity, and TB-IRIS; thereby posing enormous challenges for clinical interventions. We aim to address following issues:

  • Identifying novel/repurposed compounds as host-directed therapeutics for treatment of TB-HIV co-infections.
  • Development of 3-D human tissue organoids to model HIV and TB co-morbidity.
  • Evaluation of MDSC-directed therapeutic approaches for Tuberculosis treatment.

To fulfil these objectives, we are using various immunological, microbiological, molecular biology techniques such as flow cytometry, confocal microscopy, live cell imaging, 3-D cell culture, sequencing, luminex, qRT-PCR. These projects require work in both BSL-2 and BSL-3 settings.
SNo Authors Title of Article Pid Journal Year